The text provides unaudited financial information for Boston Scientific Corporation and its subsidiaries, with details on consolidated statements of operations, comprehensive income, balance sheets, statements of stockholders' equity, and cash flows for the three months ending March 31, 2023, compared to the same period in 2022. It also includes supplemental information on stock-based compensation, cash balances, and recent acquisitions. The financial performance shows an increase in net sales and gross profit, along with changes in various income and expense categories. Additionally, it contains details on interest expense, the effects of hedging relationships on accumulated other comprehensive income, fair value measurements for derivative and non-derivative instruments, and breakdowns of assets and liabilities. The text covers recurring and non-recurring fair value measurements, debt obligations, and a breakdown of long-term debt obligations for the company, all presented in accordance with U.S. Generally Accepted Accounting Principles and includes additional disclosures on presentation basis and subsequent events.
Boston Scientific Corporation is a global company specializing in medical devices. In Q1 2023, their net sales increased by 12.0% to $3.389 billion, primarily driven by acquisitions and product portfolio strength. Adjusted net income attributable to common stockholders was $673 million. The company's different segments, such as Cardiology and MedSurg, showed growth in net sales. Operational net sales growth excludes currency impacts and M&A inflows. The company focuses on continuous improvement, financial management, and compliance with safety protocols. It also addresses various risks and uncertainties that could impact future performance. Boston Scientific prioritizes innovation, sustainability, and global market expansion.
The company engages in a risk management program to address market risks from currency exchange rates and interest rates. They utilize derivative financial instruments to manage exposure, but not for speculative purposes. Currency risk includes firm commitments and investments in subsidiaries, managed through derivative and nonderivative instruments. Interest rate risk is managed through interest rate derivative instruments and fixed rate borrowings. The company holds significant outstanding derivatives for both currency and interest rate risks and offsets gains and losses on these instruments against underlying exposures effectively. More detailed information is available in the unaudited consolidated financial statements.
The company's management, including the CEO and CFO, evaluated the effectiveness of the disclosure controls and procedures as of March 31, 2023, finding them to be effective. The company has initiated the implementation of a new global ERP system which is expected to impact internal control over financial reporting. This transition will occur over the next few years, leading to evaluations of its impact on internal controls periodically.
Please refer to Note G - Income Taxes and Note H - Commitments and Contingencies in the unaudited consolidated financial statements in this Quarterly Report on Form 10-Q for information on legal proceedings.
Consider the information provided in Part I, Item 1A: Risk Factors from the most recent Annual Report filed on Form 10-K, as it outlines factors that could significantly impact the business, financial condition, or future outcomes.
Got it! Please go ahead and provide the text you would like me to summarize.
I'm sorry but I cannot complete tasks that require multiple responses. Can you please send me the complete text or provide me with more context so that I can help summarize it for you?
I'm here to help. Please go ahead and provide the text parts for me to summarize.
I'm sorry, but I haven't received any previous parts of the text. Please provide the text you would like me to summarize.
The text provided includes a list of exhibits filed with a report by Boston Scientific Corporation. It includes details about amendments to credit agreements, stock option agreements, subsidiary issuer information, and certifications by the CEO and CFO. The report includes Inline XBRL documents and interactive data files. The signing details of the report are also included, indicating that the report was signed by Daniel J. Brennan, the Executive Vice President and Chief Financial Officer, on behalf of Boston Scientific Corporation.
